Oxaliplatin and Topotecan in Treating Patients With Previously Treated Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer

Inclusion Criteria

• •DISEASE CHARACTERISTICS:
• •Histologically or cytologically confirmed ovarian epithelial cancer, primary peritoneal cancer, or fallopian tube cancer
• •* Prior chemotherapy required
• •Measurable or evaluable disease
• •No symptomatic, untreated brain metastases
• •PATIENT CHARACTERISTICS:
• •Age:
• •18 and over
• •Performance status:
• •Karnofsky 70-100%
• •Life expectancy:
• •At least 4 months
• •Hematopoietic:
• •WBC greater than 3,000/mm\^3
• •Absolute neutrophil count greater than 1,500/mm\^3
• •Platelet count greater than 100,000/mm\^3
• •Hepatic:
• •Bilirubin no greater than 1.5 times upper limit of normal (ULN) OR
• •SGOT no greater than 2.5 times ULN (5 times ULN if liver metastases)
• •Renal:
• •Creatinine no greater than 1.5 times ULN OR
• •Creatinine clearance at least 50 mL/min
• •Cardiovascular:
• •No uncontrolled symptomatic congestive heart failure
• •No unstable angina pectoris
• •No uncontrolled cardiac arrhythmia
• •Other:
• •No other active cancer
• •No prior allergy to platinum compounds
• •No prior allergic reactions to appropriate antiemetics (e.g., serotonin or antagonists) administered concurrently with study
• •No other uncontrolled concurrent illness (e.g., infection)
• •Not pregnant or nursing
• •Negative pregnancy test
• •Fertile patients must use effective contraception during and for 6 months after study therapy
• •PRIOR CONCURRENT THERAPY:
• •Biologic therapy:
• •See Chemotherapy
• •No concurrent colony stimulating factors during topotecan administration
• •Chemotherapy:
• •See Disease Characteristics
• •No prior high-dose chemotherapy requiring bone marrow or peripheral blood stem cell transplantation
• •At least 4 weeks since prior chemotherapy and recovered
• •Endocrine therapy:
• •Not specified
• •Radiotherapy:
• •No prior radiotherapy to whole pelvic field
• •At least 2 weeks since prior radiotherapy and recovered
• •Surgery:
• •No unresolved sequelae resulting from prior surgery
• •Other:
• •At least 4 weeks since other prior investigational drug
• •No other concurrent investigational agents
• •No other concurrent anticancer therapy